Related Experiment Video
Updated: May 24, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect
Marco Gerlinger1, Claudio R Santos, Bradley Spencer-Dene
1Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, Lincoln's Inn Fields, London, WC2A 3LY, UK.
Abstract:
Clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype of kidney cancer. Here, we integrated an unbiased genome-wide RNA interference screen for ccRCC survival regulators with an analysis of recurrently overexpressed genes in ccRCC to identify new therapeutic targets in this disease. One of the most potent survival regulators, the monocarboxylate transporter MCT4 (SLC16A3), impaired ccRCC viability in all eight ccRCC lines tested and was the seventh most overexpressed gene in a meta-analysis of five ccRCC expression datasets. MCT4 silencing impaired secretion of lactate generated through glycolysis and induced cell cycle arrest and apoptosis. Silencing MCT4 resulted in intracellular acidosis, and reduction in intracellular ATP production together with partial reversion of the Warburg effect in ccRCC cell lines. Intra-tumoural heterogeneity in the intensity of MCT4 protein expression was observed in primary ccRCCs. MCT4 protein expression analysis based on the highest intensity of expression in primary ccRCCs was associated with poorer relapse-free survival, whereas modal intensity correlated with Fuhrman nuclear grade. Consistent with the potential selection of subclones enriched for MCT4 expression during disease progression, MCT4 expression was greater at sites of metastatic disease. These data suggest that MCT4 may serve as a novel metabolic target to reverse the Warburg effect and limit disease progression in ccRCC.
Insights
Targeting monocarboxylate transporter MCT4 (SLC16A3) could be a new strategy for clear cell renal cell carcinoma (ccRCC). Silencing MCT4 in ccRCC cells impacts metabolism, survival, and disease progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer subtype.
- Identifying novel therapeutic targets is crucial for improving ccRCC outcomes.
Purpose of the Study:
- To identify new therapeutic targets for ccRCC by integrating RNA interference screening with gene expression analysis.
- To investigate the role of monocarboxylate transporter MCT4 (SLC16A3) as a potential therapeutic target in ccRCC.
Main Methods:
- Genome-wide RNA interference screen for ccRCC survival regulators.
- Meta-analysis of ccRCC expression datasets to identify overexpressed genes.
- MCT4 silencing in ccRCC cell lines and analysis of metabolic and cellular effects.
- Analysis of MCT4 protein expression in primary and metastatic ccRCC tissues.
Main Results:
- MCT4 (SLC16A3) was identified as a potent survival regulator and is highly overexpressed in ccRCC.
- MCT4 silencing impaired ccRCC cell viability, lactate secretion, and induced cell cycle arrest and apoptosis.
- MCT4 silencing led to intracellular acidosis, reduced ATP production, and partial reversion of the Warburg effect.
- Higher MCT4 expression correlated with poorer relapse-free survival and higher Fuhrman nuclear grade in ccRCC.
- MCT4 expression was elevated in metastatic ccRCC compared to primary tumors.
Conclusions:
- MCT4 is a significant survival regulator in ccRCC and a potential therapeutic target.
- Targeting MCT4 may reverse the Warburg effect and limit ccRCC progression.
- MCT4 expression levels can serve as a prognostic biomarker in ccRCC.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs
MicroRNAs